Compare Stocks

2 / 10
Try these comparisons:

Stock Comparison

SHC vs ICLR

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
SHC
Sotera Health Company

Medical - Diagnostics & Research

HealthcareNASDAQ • US
Market Cap$4.50B
5Y Perf.-41.7%
ICLR
ICON Public Limited Company

Medical - Diagnostics & Research

HealthcareNASDAQ • IE
Market Cap$9.51B
5Y Perf.-36.1%

SHC vs ICLR — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
SHC logoSHC
ICLR logoICLR
IndustryMedical - Diagnostics & ResearchMedical - Diagnostics & Research
Market Cap$4.50B$9.51B
Revenue (TTM)$1.19B$8.10B
Net Income (TTM)$118M$599M
Gross Margin55.3%26.9%
Operating Margin34.9%12.2%
Forward P/E16.2x10.7x
Total Debt$2.27B$3.60B
Cash & Equiv.$346M$539M

SHC vs ICLRLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

SHC
ICLR
StockNov 20May 26Return
Sotera Health Compa… (SHC)10058.3-41.7%
ICON Public Limited… (ICLR)10063.9-36.1%

Price return only. Dividends and distributions are not included.

Quick Verdict: SHC vs ICLR

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: SHC leads in 5 of 7 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. ICON Public Limited Company is the stronger pick specifically for valuation and capital efficiency. As sector peers, any of these can serve as alternatives in the same allocation.
SHC
Sotera Health Company
The Income Pick

SHC carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.

  • Dividend streak 2 yrs, beta 1.34
  • Rev growth 5.7%, EPS growth 68.8%, 3Y rev CAGR 5.1%
  • Lower volatility, beta 1.34, current ratio 2.46x
Best for: income & stability and growth exposure
ICLR
ICON Public Limited Company
The Long-Run Compounder

ICLR is the clearest fit if your priority is long-term compounding.

  • 90.2% 10Y total return vs SHC's -37.1%
  • Lower P/E (10.7x vs 16.2x)
Best for: long-term compounding
See the full category breakdown
CategoryWinnerWhy
GrowthSHC logoSHC5.7% revenue growth vs ICLR's 2.0%
ValueICLR logoICLRLower P/E (10.7x vs 16.2x)
Quality / MarginsSHC logoSHC9.9% margin vs ICLR's 7.4%
Stability / SafetySHC logoSHCBeta 1.34 vs ICLR's 1.64
DividendsTieNeither stock pays a meaningful dividend
Momentum (1Y)SHC logoSHC+19.3% vs ICLR's -10.1%
Efficiency (ROA)SHC logoSHC3.7% ROA vs ICLR's 3.6%, ROIC 11.8% vs 6.5%

SHC vs ICLR — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

SHCSotera Health Company
FY 2025
Service
85.6%$996M
Product
14.4%$168M
ICLRICON Public Limited Company
FY 2012
Clinical Research
92.2%$1.0B
Central Laboratory
7.8%$87M

SHC vs ICLR — Financial Metrics

Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLSHCLAGGINGICLR

Income & Cash Flow (Last 12 Months)

SHC leads this category, winning 5 of 6 comparable metrics.

ICLR is the larger business by revenue, generating $8.1B annually — 6.8x SHC's $1.2B. Profitability is closely matched — net margins range from 9.9% (SHC) to 7.4% (ICLR). On growth, SHC holds the edge at +10.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricSHC logoSHCSotera Health Com…ICLR logoICLRICON Public Limit…
RevenueTrailing 12 months$1.2B$8.1B
EBITDAEarnings before interest/tax$517M$1.4B
Net IncomeAfter-tax profit$118M$599M
Free Cash FlowCash after capex$112M$996M
Gross MarginGross profit ÷ Revenue+55.3%+26.9%
Operating MarginEBIT ÷ Revenue+34.9%+12.2%
Net MarginNet income ÷ Revenue+9.9%+7.4%
FCF MarginFCF ÷ Revenue+9.4%+12.3%
Rev. Growth (YoY)Latest quarter vs prior year+10.0%+0.6%
EPS Growth (YoY)Latest quarter vs prior year+2.9%-98.7%
SHC leads this category, winning 5 of 6 comparable metrics.

Valuation Metrics

ICLR leads this category, winning 6 of 6 comparable metrics.

At 13.1x trailing earnings, ICLR trades at a 78% valuation discount to SHC's 58.4x P/E. On an enterprise value basis, ICLR's 7.9x EV/EBITDA is more attractive than SHC's 21.2x.

MetricSHC logoSHCSotera Health Com…ICLR logoICLRICON Public Limit…
Market CapShares × price$4.5B$9.5B
Enterprise ValueMkt cap + debt − cash$6.4B$12.6B
Trailing P/EPrice ÷ TTM EPS58.44x13.06x
Forward P/EPrice ÷ next-FY EPS est.16.23x10.73x
PEG RatioP/E ÷ EPS growth rate1.86x
EV / EBITDAEnterprise value multiple21.20x7.92x
Price / SalesMarket cap ÷ Revenue3.87x1.15x
Price / BookPrice ÷ Book value/share7.46x1.09x
Price / FCFMarket cap ÷ FCF30.16x8.50x
ICLR leads this category, winning 6 of 6 comparable metrics.

Profitability & Efficiency

SHC leads this category, winning 6 of 9 comparable metrics.

SHC delivers a 20.6% return on equity — every $100 of shareholder capital generates $21 in annual profit, vs $6 for ICLR. ICLR carries lower financial leverage with a 0.38x debt-to-equity ratio, signaling a more conservative balance sheet compared to SHC's 3.75x. On the Piotroski fundamental quality scale (0–9), ICLR scores 7/9 vs SHC's 6/9, reflecting strong financial health.

MetricSHC logoSHCSotera Health Com…ICLR logoICLRICON Public Limit…
ROE (TTM)Return on equity+20.6%+6.3%
ROA (TTM)Return on assets+3.7%+3.6%
ROICReturn on invested capital+11.8%+6.5%
ROCEReturn on capital employed+13.3%+7.8%
Piotroski ScoreFundamental quality 0–967
Debt / EquityFinancial leverage3.75x0.38x
Net DebtTotal debt minus cash$1.9B$3.1B
Cash & Equiv.Liquid assets$346M$539M
Total DebtShort + long-term debt$2.3B$3.6B
Interest CoverageEBIT ÷ Interest expense2.38x3.96x
SHC leads this category, winning 6 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

SHC leads this category, winning 5 of 6 comparable metrics.

A $10,000 investment in SHC five years ago would be worth $6,567 today (with dividends reinvested), compared to $5,523 for ICLR. Over the past 12 months, SHC leads with a +19.3% total return vs ICLR's -10.1%. The 3-year compound annual growth rate (CAGR) favors SHC at 1.7% vs ICLR's -13.1% — a key indicator of consistent wealth creation.

MetricSHC logoSHCSotera Health Com…ICLR logoICLRICON Public Limit…
YTD ReturnYear-to-date-10.8%-34.0%
1-Year ReturnPast 12 months+19.3%-10.1%
3-Year ReturnCumulative with dividends+5.3%-34.4%
5-Year ReturnCumulative with dividends-34.3%-44.8%
10-Year ReturnCumulative with dividends-37.1%+90.2%
CAGR (3Y)Annualised 3-year return+1.7%-13.1%
SHC leads this category, winning 5 of 6 comparable metrics.

Risk & Volatility

SHC leads this category, winning 2 of 2 comparable metrics.

SHC is the less volatile stock with a 1.34 beta — it tends to amplify market swings less than ICLR's 1.64 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SHC currently trades 79.5% from its 52-week high vs ICLR's 59.0% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricSHC logoSHCSotera Health Com…ICLR logoICLRICON Public Limit…
Beta (5Y)Sensitivity to S&P 5001.34x1.64x
52-Week HighHighest price in past year$19.85$211.00
52-Week LowLowest price in past year$10.80$66.57
% of 52W HighCurrent price vs 52-week peak+79.5%+59.0%
RSI (14)Momentum oscillator 0–10054.162.8
Avg Volume (50D)Average daily shares traded3.1M1.1M
SHC leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Wall Street rates SHC as "Buy" and ICLR as "Buy". Consensus price targets imply 39.4% upside for SHC (target: $22) vs 22.2% for ICLR (target: $152).

MetricSHC logoSHCSotera Health Com…ICLR logoICLRICON Public Limit…
Analyst RatingConsensus buy/hold/sellBuyBuy
Price TargetConsensus 12-month target$22.00$152.13
# AnalystsCovering analysts1230
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises2
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+5.3%
Insufficient data to determine a leader in this category.
Key Takeaway

SHC leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). ICLR leads in 1 (Valuation Metrics).

Best OverallSotera Health Company (SHC)Leads 4 of 6 categories
Loading custom metrics...

SHC vs ICLR: Frequently Asked Questions

10 questions · data-driven answers · updated daily

01

Is SHC or ICLR a better buy right now?

For growth investors, Sotera Health Company (SHC) is the stronger pick with 5.

7% revenue growth year-over-year, versus 2. 0% for ICON Public Limited Company (ICLR). ICON Public Limited Company (ICLR) offers the better valuation at 13. 1x trailing P/E (10. 7x forward), making it the more compelling value choice. Analysts rate Sotera Health Company (SHC) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — SHC or ICLR?

On trailing P/E, ICON Public Limited Company (ICLR) is the cheapest at 13.

1x versus Sotera Health Company at 58. 4x. On forward P/E, ICON Public Limited Company is actually cheaper at 10. 7x.

03

Which is the better long-term investment — SHC or ICLR?

Over the past 5 years, Sotera Health Company (SHC) delivered a total return of -34.

3%, compared to -44. 8% for ICON Public Limited Company (ICLR). Over 10 years, the gap is even starker: ICLR returned +90. 2% versus SHC's -37. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — SHC or ICLR?

By beta (market sensitivity over 5 years), Sotera Health Company (SHC) is the lower-risk stock at 1.

34β versus ICON Public Limited Company's 1. 64β — meaning ICLR is approximately 22% more volatile than SHC relative to the S&P 500. On balance sheet safety, ICON Public Limited Company (ICLR) carries a lower debt/equity ratio of 38% versus 4% for Sotera Health Company — giving it more financial flexibility in a downturn.

05

Which is growing faster — SHC or ICLR?

By revenue growth (latest reported year), Sotera Health Company (SHC) is pulling ahead at 5.

7% versus 2. 0% for ICON Public Limited Company (ICLR). On earnings-per-share growth, the picture is similar: Sotera Health Company grew EPS 68. 8% year-over-year, compared to 28. 8% for ICON Public Limited Company. Over a 3-year CAGR, ICLR leads at 14. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — SHC or ICLR?

ICON Public Limited Company (ICLR) is the more profitable company, earning 9.

6% net margin versus 6. 7% for Sotera Health Company — meaning it keeps 9. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SHC leads at 33. 8% versus 13. 3% for ICLR. At the gross margin level — before operating expenses — SHC leads at 55. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is SHC or ICLR more undervalued right now?

On forward earnings alone, ICON Public Limited Company (ICLR) trades at 10.

7x forward P/E versus 16. 2x for Sotera Health Company — 5. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SHC: 39. 4% to $22. 00.

08

Which pays a better dividend — SHC or ICLR?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is SHC or ICLR better for a retirement portfolio?

For long-horizon retirement investors, Sotera Health Company (SHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.

ICON Public Limited Company (ICLR) carries a higher beta of 1. 64 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SHC: -37. 1%, ICLR: +90. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between SHC and ICLR?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SHC is a small-cap quality compounder stock; ICLR is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.

Stocks Like

SHC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 5%
  • Net Margin > 5%
Run This Screen
Stocks Like

ICLR

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Net Margin > 5%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform SHC and ICLR on the metrics below

Revenue Growth>
%
(SHC: 10.0% · ICLR: 0.6%)
Net Margin>
%
(SHC: 9.9% · ICLR: 7.4%)
P/E Ratio<
x
(SHC: 58.4x · ICLR: 13.1x)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.